Travel Grants to AACR 2017 Announced

Proteintech Group repeats sponsorship of two $1,000 merit-based scholarships to attend #AACR17

Written by CG Life for Proteintech Group

CHICAGO—February 20, 2017—Proteintech Group, the benchmark in antibodies, today announced the start of its annual travel grant contest for the 2017 American Association for Cancer Research (AACR) meeting. The two winners will each receive a $1,000 grant towards accommodations and travel for this meeting. AACR 2017 will be held April 1-5 in Washington, D.C. Recipients may use the money to cover event registration fees, airfare and accommodations.

The travel award is open to any cancer researcher based at a university or research institution. Application requires a researcher to submit a summary of current research or a copy of his or her abstract being presented at AACR 2017 to the official contest website. New this year, the independent, international panel that selects the winners exclusively comprises post-doctoral fellows and graduate students.

“We need to invest in early-career researchers,” said Jason Li, PhD, CEO of Proteintech. “That means providing them with ample opportunities and challenges to grow as scientists. Our highly qualified panel will reward the most original and valuable studies in cancer.”

The AACR Annual Meeting attracts more than 18,000 attendees from more than 60 countries each spring, including 2016 winner Ariella Hanker.

“I made several new contacts at AACR with whom I am now collaborating,” said Hanker, research instructor of medicine at Vanderbilt University. “I always leave AACR feeling energized about my research and optimistic about the progress we’re making in the fight against cancer.”

Only the first 200 entries submitted before the deadline of March 6 will be accepted, and the winners will be announced on March 13, 2017. All embargo policies set by AACR will be respected.

To apply for the Proteintech travel grant award for #AACR17, or for official rules, terms and conditions, please visit bit.ly/2l5zAgl.